X-linked Hypophosphatemia (XLH) Treatment Market Growth Rate, Share, Size, Opportunity, Demand and Forecast to 2030 (2023)

Global X-Linked Hypophosphatemia (XLH) Treatment Market by Type (Form ofhypophosphatemiarickets), treatment (standard hormone therapies, surgery,phosphateDietary Supplements), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.

X-Linked Hypophosphatemia (XLH) Treatment Market Analysis and Size

According to statistics released by the FDA in 2017, XLH affected approximately 3,000 children and 12,000 adults in the United States. The disorder is generally diagnosed in children with symptoms such as bent or bent legs, severe tooth and bone pain, and short stature. This is due to the mutation in the PHEX gene on the X chromosome. In addition, according to the study published in May 2016 by the NIHR Horizon Scanning Research & Intelligence Center, more than 500 children in the UK have been affected by XLH.

Data Bridge Market Research analyzes a growth rate in the X-Linked Hypophosphatemia (XLH) Treatment Market during the forecast period 2023-2030. The expected CAGR of the X-linked hypophosphatemia (XLH) treatment market tends to be around 10% during the mentioned forecast period. The market was valued at $1 billion in 2022 and would grow to $2.14 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographic coverage, market players, and market scenario, the market report prepared by Data Bridge market research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

X-linked Hypophosphatemia (XLH) Treatment Market Scope and Segmentation

Market definition

X-linked hypophosphatemia (XLH) is an inherited disorder typically characterized by low levels of phosphate in the blood. Phosphorus levels tend to be low in these patients because phosphate is abnormally stored in the kidneys, causing the urine to lose phosphate and leading to poor, weak bones (rickets). X-linked hypophosphatemia (XLH) is usually diagnosed in children. The disorder is inherited in an X-linked dominant manner because the gene responsible for the condition is on the X chromosome. In addition, women with X-linked hypophosphatemia (XLH) have a 50% chance of passing the disorder on to their children.

Global Market Dynamics of X-Linked Hypophosphatemia (XLH) Treatment.

driver

• High prevalence of X-linked hypophosphatemia (XLH)

According to statistics published in 2016 by the European Journal of Endocrinology, the occurrence of XLH was estimated at 3.9 per 100,000 live births and an incidence of 4.8 per 100,000 people. To date, there have been around 250 children and adolescents with XLH and up to 2,500 adults in England, according to the report published in 2017 by the National Institute for Health and Care Excellence.

• Rising healthcare spending

Increasing research funding for several rare diseases like XLH and high healthcare spending are also expected to boost the growth of the market over the forecast period. For example, Genome Canada and the Canadian Institutes for Health Research have partnered to study rare genetic diseases using next-generation sequencing (NGS) technology. Thus, this factor has impacted tremendous growth of the market.

occasions

• increase in the elderly population

It is estimated that the market will register a strong growth rate during the forecast period, which will be driven by the factor of an aging population. The increasing demand in the market is to replicate the increasing elderly population as people over the age of 60 often develop weak immunity and this in turn impairs normal functioning. This promotes market growth.

• Rising drug approvals from XLH

Numerous recent approvals of drugs for X-linked hypophosphatemia (XLH) by regulatory authorities worldwide are expected to boost the growth of the market over the forecast period. For example, in December 2018, Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd announced Heath Canada's approval of Crysvita, a burosumab injection, to better treat X-linked hypophosphatemia (XLH) in adult and pediatric patients.

Limitations/Challenges

• Lack of qualified professionals

The shortage of qualified healthcare professionals who cannot perform the treatments could reduce the growth of the global X-linked hypophosphatemia (XLH) treatment market during the forecast period.

• Side effects of X-linked hypophosphatemia (XLH) treatment

The adverse side effects associated with the treatment process are hampering the market growth. Effects such as hearing loss, infections, and also some medications can lead to autoimmune reactions.

This X-Linked Hypophosphatemia (XLH) Treatment Market report provides details on new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market shares, impact of domestic and local market players and analyzes opportunities in terms of emerging revenue pockets, Changes in market regulation, strategic market growth analysis, market size, category market growth, application niches and dominance, product approvals, product launches, geographic expansion, technological innovations in the market. For more information on the X-Linked Hypophosphatemia (XLH) Treatment Market, contact Data Bridge Market Research to receive an analyst letter. Our team will help you make an informed market decision to achieve market growth.

Global X-Linked Hypophosphatemia (XLH) Treatment Market Size.

The X-linked hypophosphatemia (XLH) treatment market is segmented by type, treatment, end-user and distribution channel. The growth in these segments will help you analyze lean growth segments in the industries, providing users with valuable market overview and market insights to help them make strategic decisions to identify core market applications.

Typ

• form of hypophosphatemia rickets

Treatment

• Standard-Hormontherapien
• Operation
• phosphate supplements

End User

• hospitals
• specialty clinics
• Others

distribution channel

• hospital pharmacy
• retail pharmacy
• Others

Global X-Linked Hypophosphatemia (XLH) Treatment Market Regional Analysis/Insights

The X-Linked Hypophosphatemia (XLH) Treatment market is analyzed providing insights into market size and trends by type, treatment, end-user and distribution channel as stated above.

Major Countries covered in X-Linked Hypophosphatemia (XLH) Treatment market reportare USA, Canada and Mexico in North America, Germany, France, UK, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia , Australia, Thailand, Indonesia, Philippines, Rest of Asia Pacific (APAC) Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as part of Middle East and Africa (MEA), Brazil, Argentina and the rest of South America as part of South America.

North America dominates the market due to the increasing prevalence of X-linked hypophosphatemia (XLH) treatment in the US and Canada and the presence of a well-established healthcare sector.

The Asia-Pacific region is expected to be the largest market due to the increasing prevalence of hypertension, kidney and liver diseases and the number of common diseases.

The country section of the report also includes individual market influencing factors and domestic regulatory changes impacting the current and future trends of the market. It also considers the presence and availability of global brands and their challenges due to high or low competition from local and domestic brands, the impact of domestic tariffs and trade routes while providing a forecast analysis of the country data.

X-Linked Hypophosphatemia (XLH) Treatment Competitive Landscape and Global Market Share Analysis.

X-Linked Hypophosphatemia (XLH) Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, R&D investments, new market initiatives, global footprint, manufacturing locations and facilities, manufacturing capabilities, company strengths and weaknesses, product launch, product breadth and breadth, application dominance. The data points provided above are only related to the companies' focus regarding the X-Linked Hypophosphatemia (XLH) Treatment market.

Major Players in X-Linked Hypophosphatemia (XLH) Treatment Market Include:

• Kyowa Kirin Co., Ltd. (Japan
• Smith+Nephew (UK)
• Nestlé (Switzerland)
• Pfizer, Inc. (USA)
• Koninklijke Philips N.V. (Netherlands)
• ADM Animal Nutrition (USA)
• Ultragenyx Pharmaceutical (USA)
• Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
• Lilly (USA)
• F. Hoffmann-La Roche AG (Switzerland)

Item number-56385